2022 Regular Session

HOUSE BILL NO. 378

BY REPRESENTATIVE MARINO

DRUGS/CONTROLLED: Adds certain substances to the Uniform Controlled Dangerous Substances Law

AN ACT

To amend and reenact R.S. 40:964(Schedule II)(A)(1)(introductory paragraph) and to enact R.S. 40:964(Schedule I)(A)(80) through (101), (C)(66), (E)(12), and (F)(29) through (34), and (Schedule IV)(D)(15), relative to the Uniform Controlled Dangerous Substances Law; to add certain substances to Schedules I and IV; to provide relative to substances of vegetable origin or chemical synthesis in Schedule II; and to provide for related matters.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 40:964(Schedule II)(A)(1)(introductory paragraph) is hereby amended and reenacted and R.S. 40:964(Schedule I)(A)(80) through (101), (C)(66), (E)(12), and (F)(29) through (34) and (Schedule IV)(D)(15) are hereby enacted to read as follows:

§964. Composition of schedules

Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S. 40:962, consist of the following drugs or other substances, by whatever official name, common or usual name, chemical name, or brand name designated:

SCHEDULE I

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, or salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

*    *    *

CODING: Words in struck through type are deletions from existing law; words underscored are additions.
(80) Phenylfentanyl
(81) para-methylfentanyl
(82) Thiofuranylfentanyl
(83) beta-methylfentanyl
(84) beta-phenylfentanyl
(85) 2-fluoro-orthofluorofentanyl
(86) 4-methylacetylfentanyl
(87) Orthofluorobutyrylfentanyl
(88) Orthomethylacetylfentanyl
(89) Orthomethylmethoxyacetylfentanyl
(90) Orthofluoroacrylfentanyl
(91) Fentanyl carbamate
(92) Orthofluoroisobutyrylfentanyl
(93) para-fluorofuranylfentanyl
(94) Isotonitazene (N,N-diethyl-2-[(4-isopropoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)
(95) Metonitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)
(96) Butonitazene (N,N-diethyl-2-[(4-butoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)
(97) Flunitazene (N,N-diethyl-2-(4-fluorophenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)
(98) Protonitazene (N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine)
(99) N-pyrrolidino etonitazene (2-[(4-ethoxyphenyl)methyl]-5-nitro-1-[2-(pyrrolidino-1-yl)ethyl]-1H-benzimidazole)
(100) Etodesnitazene (N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-1H-benzimidazole-1-ethanamine)
(101) Metodesnitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-
1 H-benzimidazole-1-ethanamine

* * *

C. Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, for purposes of this Paragraph only, the term "isomer" includes the optical, position, and geometric isomers:

* * *

(66) para-methoxymethamphetamine (PMMA)

* * *

E. Stimulants. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States federal Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including its salts, isomers, esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible within the specific chemical designation:

* * *

(12) 4,4-dimethylaminorex (4,4-DMAR)

F. Synthetic cannabinoids. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of a synthetic cannabinoid found to be in any of the following individual compounds or chemical groups, or any of those individual compounds or groups which contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the
existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs
is possible within the specific compounds or chemical groups:

* * *

(29) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-B]
pyridine-3-carboxamide [5FCUMYL-P7AICA]

(30) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
[CBL2201]

(31) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-
3-carboxamide [5F-AB-PINACA]

(32) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
[4-CN-CUMYL-BUTINACA]

(33) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methyl-
butanoate [MMB-CHMICA; AMB-CHMICA]

(34) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
[N-ethylpentyline; ephylone]

* * *

SCHEDULE II

A. Substances of vegetable origin or chemical synthesis. Unless specifically
excepted or unless listed in another schedule, any of the following substances
whether produced directly or indirectly by extraction from substances of vegetable
origin, or independently by means of chemical synthesis, or by a combination of
extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of
opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan,
nalbuphine, naldemedine, nalmefene, naloxygol, naloxone, 6β-naltrexol, and
naltrexone, and samidorphan, and their respective salts, but including the following:

* * *

SCHEDULE IV

* * *
D. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers:

* * *

\(15\) Serdexmethylphenidate

* * *

Section 2. The Louisiana State Law Institute is hereby authorized and directed to renumber the substances in R.S. 40:964(Schedule I)(A),(C), and (E) and (Schedule V)(D) to ensure that such substances are in alphabetical order.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 378 Original 2022 Regular Session Marino

Abstract: Adds certain substances to Schedules I, II, and IV of the Uniform Controlled Dangerous Substances Law.

Present law provides for the designation of controlled dangerous substances into Schedules I, II, III, IV, and V based upon the substances' potential for addiction and abuse.

Proposed law adds 31 additional substances to Schedule I and Serdexmethylphenidate to Schedule IV.

Proposed law adds samidorphan as a Schedule II substance of vegetable origin.

(Amends R.S. 40:964(Schedule II)(A)(1)(intro. para.); Adds R.S. 40:964(Schedule I)(A)(80)-(101), (C)(66), (E)(12), and (F)(29)-(34), and (Schedule IV)(D)(15))